2 Information about avelumab

Marketing authorisation indication

2.1 Avelumab (Bavencio, Merck Serono) is indicated 'as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial cancer who are progression-free following platinum-based chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for avelumab.


2.3 The list price is £768.00 per 200 mg/10 ml concentrate for solution for infusion vials (excluding VAT; BNF online, accessed February 2022).

2.4 The company has a commercial arrangement. This makes avelumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)